Related references
Note: Only part of the references are listed.The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study
Benjamin Kearns et al.
VALUE IN HEALTH (2021)
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
Mario J. N. M. Ouwens et al.
PHARMACOECONOMICS (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade
Stefan Zimmermann et al.
JAMA ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Scott J. Antonia et al.
LANCET ONCOLOGY (2019)
Novel patterns of response under immunotherapy
E. Borcoman et al.
ANNALS OF ONCOLOGY (2019)
Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors
Alexandre Vivot et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?
Boris Freidlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A. Ascierto et al.
JAMA ONCOLOGY (2019)
Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale
Louis Everest et al.
JAMA NETWORK OPEN (2019)
Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?
Everardo D. Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?
Everardo D. Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Data maturity and follow-up in time-to-event analyses
Val Gebski et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2018)
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Louis Fehrenbacher et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy
Brian M. Alexander et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation
Eddie Gibson et al.
PHARMACOECONOMICS (2017)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
A reconstructed melanoma data set for evaluating differential treatment benefit according to biomarker subgroups
Jaya M. Satagopan et al.
DATA IN BRIEF (2017)
Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials
Ludovic Trinquart et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
Karel G. M. Moons et al.
ANNALS OF INTERNAL MEDICINE (2015)
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
Tai-Tsang Chen
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
Tai-Tsang Chen
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial
Fredrik Warnberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
Hajime Uno et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Cure Models as a Useful Statistical Tool for Analyzing Survival
Megan Othus et al.
CLINICAL CANCER RESEARCH (2012)
Fitting and modeling cure in population-based cancer studies within the framework of flexible parametric survival models
Therese M. -L. Andersson et al.
STATA JOURNAL (2012)
Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models
Therese M. L. Andersson et al.
BMC MEDICAL RESEARCH METHODOLOGY (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Hazards of Hazard Ratios
Miguel A. Hernan
EPIDEMIOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cautionary Note Regarding the Use of CIs Obtained From Kaplan-Meier Survival Curves
Rickey E. Carter et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Share Paper
